Clinical trial
Rosiglitazone Effect on Mitochondria and Lipoatrophy
NCT00367744 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00367744 |
|---|---|
| Title | Rosiglitazone Effect on Mitochondria and Lipoatrophy |
| Official title | Placebo Controlled Study of Rosiglitazone in HIV Lipoatrophy |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Rosiglitazone, Placebo |
| Enrollment | 71 |
| Start date | Jul 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Aug 23, 2006 |
| Last update posted | Feb 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: